You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2024

Details for Patent: 5,344,658


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,344,658
Title: Process and composition using ondansetron
Abstract:The invention relates to a process for reducing the crystal size of ondansetron hydrochloride dihydrate produced by crystallisation from solvent to a size which is suitable for effective distribution in a tablet blend, in particular 100% less that 250 .mu.m. The ondansetron hydrochloride dihydrate is desolvated by drying at elevated temperature and reduced or atmospheric pressure and is then rehydrated.
Inventor(s): Collin; David T. (Ware, GB2)
Assignee: Glaxo Group Limited (London, GB2)
Application Number:08/005,736
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Process; Composition;
Patent landscape, scope, and claims:

United States Patent 5,344,658: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 5,344,658, titled "Process and composition using ondansetron," is a significant patent that pertains to a process for reducing the crystal size of ondansetron hydrochloride dihydrate. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background of the Patent

The patent, filed on September 6, 1991, and granted on August 30, 1994, is a continuation of earlier applications (Ser. No. 07/755,736 and Ser. No. 07/544,644), both of which were abandoned[4].

Scope of the Patent

The patent focuses on a specific process related to the pharmaceutical compound ondansetron hydrochloride dihydrate. The invention involves a method for reducing the crystal size of this compound through desolvation and resolvation. This process is crucial for improving the physical and chemical properties of the drug, such as its solubility and stability.

Desolvation and Resolvation Process

The patented process involves the removal of solvent from the ondansetron hydrochloride dihydrate crystals (desolvation) followed by the reintroduction of a solvent (resolvation). This cycle helps in achieving smaller crystal sizes, which can enhance the bioavailability and efficacy of the drug[4].

Claims of the Patent

The patent includes several claims that define the scope of the invention. Here are some key claims:

Independent Claims

  • Claim 1 describes the process of desolvating ondansetron hydrochloride dihydrate to remove solvent and then resolvating the desolvated material to form smaller crystals.
  • Claim 2 specifies the conditions under which the desolvation and resolvation are carried out, including temperature and solvent composition.

Dependent Claims

  • Dependent claims further detail the process, including the types of solvents used, the duration of the desolvation and resolvation steps, and the resulting crystal size.

These claims collectively define the boundaries of the patented process and ensure that any similar processes would infringe on this patent unless they fall outside these specified parameters[4].

Patent Landscape

Prior Art

The patent landscape for ondansetron hydrochloride dihydrate includes various prior art references that deal with the synthesis, crystallization, and formulation of this compound. The USPTO's Common Citation Document (CCD) would be a useful resource to consolidate prior art citations from multiple patent offices, helping to understand the global context of this invention[1].

Related Patents

Other patents related to ondansetron, such as those dealing with different formulations or synthesis methods, are part of the broader patent landscape. For example, patents like US 5,622,720, which also relate to ondansetron but focus on different aspects, contribute to the overall intellectual property environment surrounding this drug[5].

International Patent Offices

To fully understand the global patent landscape, it is essential to search databases from other international intellectual property offices such as the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO)[1].

Search Tools and Resources

Several tools and resources are available for conducting a thorough search of the patent landscape:

Patent Public Search

The USPTO's Patent Public Search tool is a powerful resource for searching prior art and related patents. It offers enhanced access to prior art and modern interfaces for a more efficient search process[1].

Global Dossier

The Global Dossier service provides access to the file histories of related applications from participating IP Offices, allowing users to see the patent family for a specific application and related data such as classification and citation information[1].

Patent and Trademark Resource Centers (PTRCs)

Local PTRCs offer training in patent search techniques and maintain local search resources, which can be invaluable for a detailed analysis of the patent landscape[1].

Economic and Legal Implications

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset can provide insights into the scope and trends of patent claims, including those related to pharmaceutical processes. This dataset can help in understanding the economic implications of patent claims and their impact on innovation[3].

Legal Status

As of the current date, the legal status of US 5,344,658 is listed as expired, indicating that the patent is no longer in force. This means that the process described in the patent is now in the public domain and can be freely used without infringing on any patent rights[4].

Conclusion

United States Patent 5,344,658 is a significant contribution to the field of pharmaceuticals, particularly in the processing of ondansetron hydrochloride dihydrate. Understanding the scope, claims, and broader patent landscape is crucial for researchers, manufacturers, and legal professionals involved in this field.

Key Takeaways

  • Process Innovation: The patent describes a novel process for reducing the crystal size of ondansetron hydrochloride dihydrate through desolvation and resolvation.
  • Claims Analysis: The patent includes several claims that define the specific conditions and steps of the process.
  • Patent Landscape: The landscape includes prior art, related patents, and international patent offices.
  • Search Tools: Utilize tools like Patent Public Search, Global Dossier, and PTRCs for a comprehensive search.
  • Economic and Legal Implications: The patent's expiration means the process is now in the public domain.

FAQs

Q: What is the main focus of US Patent 5,344,658?

A: The main focus is a process for reducing the crystal size of ondansetron hydrochloride dihydrate through desolvation and resolvation.

Q: What are the key claims of the patent?

A: The key claims include the process of desolvation and resolvation, and the conditions under which these steps are carried out.

Q: Is the patent still in force?

A: No, the patent has expired and is no longer in force.

Q: What tools can be used to search for related patents?

A: Tools such as Patent Public Search, Global Dossier, and resources from PTRCs can be used.

Q: Why is understanding the patent landscape important?

A: Understanding the patent landscape helps in identifying prior art, related patents, and potential legal implications, which is crucial for innovation and compliance.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. Unified Patents Portal - US-5344658-A: https://portal.unifiedpatents.com/patents/patent/US-5344658-A
  3. USPTO - Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. Google Patents - US5344658A: https://patents.google.com/patent/US5344658
  5. Google APIs - US5622720: http://patentimages.storage.googleapis.com/pdfs/US5622720.pdf

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 5,344,658

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,344,658

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom89148043Jun 28, 1989

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.